KA/EN
Register
Medicines reference
Search
Search
Active substance

Theophylline

Favourites

Methylxanthine bronchodilator. No registration in force in Georgia. Forms: modified release (retard / SR).

Dose and use

Doses

Each dose comes with its source. Check the label of the product you use.

Active substance Theophylline
Dose calculatorCalculates the active-substance amount; it is not a prescription.
PatientSpecies and weight will be filled in automatically in other calculators.
Selected dose
Dose Species Indication Route Frequency Source
20 mg/kg Dog Maintenance By mouth once daily
VMD SPC 2025
Official product label (SPC), VMD, UK
Approved by the UK Veterinary Medicines Directorate (VMD) as part of the product's authorisation. It applies to that product as authorised there.
Corvental D Hard Capsules (theophylline) - UK SPC
VMD Product Information Database, 2025
5–7 mg/kg
off-label
 Dog Maintenance By mouth 3 times daily
MSD Vet Manual 2024
Reference book
A veterinary reference written and reviewed by specialists, summarising accepted practice. The product label gives the authorised dose.
Systemic Treatment of Inflammatory Airway Disease in Animals
MSD/Merck Veterinary Manual, 2024
3 mg/kg
off-label
 Cat Maintenance By mouth 2 times daily
MSD Vet Manual 2024
Reference book
A veterinary reference written and reviewed by specialists, summarising accepted practice. The product label gives the authorised dose.
Systemic Treatment of Inflammatory Airway Disease in Animals
MSD/Merck Veterinary Manual, 2024
25 mg/kg
off-label
 Cat Maintenance By mouth once daily
MSD Vet Manual 2024
Reference book
A veterinary reference written and reviewed by specialists, summarising accepted practice. The product label gives the authorised dose.
Systemic Treatment of Inflammatory Airway Disease in Animals
MSD/Merck Veterinary Manual, 2024
Before use

Safety information

Known Contraindications

  • Critical
    Do not use theophylline in dogs with a history of epileptiform seizures. Convulsions may occur without preceding signs of toxicity, even in otherwise apparently normal animals.
    Sources: VMD SPC · VMD
  • Warning
    Use theophylline cautiously in patients with liver disease. Reduced hepatic metabolism can increase plasma concentrations, and the drug has a narrow therapeutic range.
    Sources: VMD SPC · VMD
  • Warning
    cardiac arrhythmias, CNS excitement, tremors, convulsions, and gastrointestinal irritation
    Sources: MSD Vet Manual
  • Warning
    Use theophylline in pregnant bitches only after an individual benefit-risk assessment.
    Sources: VMD SPC · VMD
  • Caution
    Only small amounts of theophylline are excreted in milk. Lactation is not an absolute contraindication, but monitor the nursing offspring and use only when the expected benefit outweighs risk.
    Sources: VMD SPC · VMD

Known Drug Interactions

  • Major warning Theophylline + Ciprofloxacin
    Serious and fatal reactions have been reported in patients receiving concurrent administration of CIPRO and theophylline. These reactions have included cardiac arrest, seizure, status epilepticus, and respiratory failure. Avoid Use (Plasma Exposure Likely to be Increased and Prolonged)
    Recommendation: Avoid concurrent use when possible. If the combination is unavoidable, monitor serum theophylline and reduce its dose as needed. Watch for nausea, vomiting, tremor, excitation, tachycardia, and seizures.
    Sources: FDA
  • Major warning Marbofloxacin + Theophylline
    Fluoroquinolones can increase serum theophylline concentrations. When marbofloxacin and theophylline are used together, monitor theophylline closely because its therapeutic range is narrow and toxicity may occur.
    Recommendation: If concomitant use is necessary, monitor serum theophylline and be prepared to reduce its dose. Alternatively, choose another antibiotic.
    Sources: VMD SPC · VMD
  • Major warning Enrofloxacin + Theophylline
    Do not use concurrently with theophylline as the elimination of theophylline may be delayed Concomitant administration of theophylline requires careful monitoring as serum levels of theophylline may increase
    Recommendation: Avoid the combination where possible. If concomitant use is unavoidable, monitor serum theophylline and be prepared to reduce its dose.
    Sources: VMD
  • Major warning Phenobarbital + Theophylline
    Plasma theophylline levels may... decrease in patients receiving phenobarbitone or phenytoin. is induced by rifampin and phenobarbital
    Recommendation: Reduced theophylline effect is expected during concomitant use. Assess clinical response and increase the dose if needed without exceeding 20 mg/kg in dogs. Theophylline levels rise when phenobarbital is stopped; reassess the dose.
    Sources: VMD SPC · VMD · MSD Vet Manual
  • Minor warning Theophylline + Methimazole
    A reduction in dose of certain drugs (β-adrenergic blocking agents, digitalis glycosides, and theophylline) may be needed when the patient becomes euthyroid.
    Recommendation: Reassess the dose once euthyroidism is achieved.
    Sources: FDA
Latin name
Theophylline
Georgian name
თეოფილინი
Authorisation status
Authorised veterinary medicine
An authorised veterinary medicine containing this substance exists. Whether a particular use is on-label depends on the species and the indication - see each dose rule.
Registered in Georgia
0 of 3 forms
Products
Corvental D
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
All forms and registration3

Registration in Georgia and abroad: the register, number, validity and source are behind (i).

Corvental D 100 mg, Modified release (retard / SR)

sustained-release hard capsule, for dogs
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog
6.4/10
Situational / acceptable
vetman assessment

Corvental D

100 mg, sustained-release hard capsule, for dogs
Assessed clinical scopeDog · Labelled once-daily sustained-release theophylline as an adjunct for canine bronchitis; the legacy congestive-heart-failure label claim requires diagnosis-led reassessment against current cardiac standard care · By mouth
Care settingVeterinary-prescribed home treatment after respiratory and cardiac diagnosis, with exact weight-based capsule selection, interaction review and response and toxicity monitoring
vetman score 6.4/10 Situational / acceptable
Evidence confidence: Medium Georgia: No · Verified on 15 Oct 2026

A currently authorised, exact canine sustained-release product with convenient once-daily dosing and the most flexible strength. It is a situational adjunct for selected bronchitis patients, not a routine substitute for diagnosis-specific respiratory or cardiac treatment; whole-capsule fit, interactions and toxicity require active management.

Regulatory and scientific credibility8.0/10

The exact dog-only sustained-release presentations are currently authorised in Great Britain as prescription veterinary medicines, with a regulator-hosted 2025 SPC and product-specific pharmacokinetic evidence. They are not registered in Georgia, the pivotal study is small and more than three decades old, and no modern public benefit-risk reassessment of the full label scope was found.

Clinical efficacy5.5/10

A six-dog sustained-release study supports the labelled exposure and documented pharmacodynamic effects, and theophylline remains a recognised adjunct for canine bronchitis. However, no robust modern clinical outcome trial of Corvental D was found, response to bronchodilators is variable, anti-inflammatory treatment remains central, and the congestive-heart-failure claim is not evidence that theophylline substitutes for current diagnosis-specific cardiac therapy.

Safety and tolerability5.5/10

The exact SPC documents restlessness, gastrointestinal effects, polyuria and CNS excitation, contraindicates seizure history and beta-sympathomimetics, and identifies major metabolism and anaesthetic interactions. The therapeutic margin is narrow, convulsions may occur without preceding toxicity signs, and there is no specific antidote; liver disease, pregnancy and concurrent medicines require individual review.

Clinical practicality6.5/10

Once-daily home dosing is convenient and the 100 mg whole capsule is the most flexible presentation, but the modified-release capsule cannot be opened or divided. At the 20 mg/kg label dose it exactly fits a 5 kg increment; dogs between exact whole-capsule combinations may require a different strength or regimen rather than rounding upward.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Do not use in dogs with a history of epileptiform seizures. Convulsions have occurred without preceding toxicity signs and in apparently normal animals.
  • Concurrent beta-sympathomimetic use is contraindicated because additive or synergistic adverse effects may occur.
  • Macrolides and fluoroquinolones can increase theophylline exposure; phenobarbital and phenytoin can reduce it. Ketamine may further lower the seizure threshold and recent halothane exposure can increase arrhythmia risk. Review every medicine before treatment.
  • The modified-release capsule must be swallowed whole. Do not open, crush, chew or divide it; damaging the release system can create an unsafe peak and an unreliable dosing interval.
  • Weigh accurately and do not exceed 20 mg/kg once daily. Select whole capsules deliberately; never round upward merely to fit a strength. Consider plasma concentration monitoring when response, adherence, interactions or toxicity are uncertain.
  • Stop and reassess promptly for vomiting, diarrhoea, marked thirst or urination, restlessness, agitation, excitement, sedation, reduced appetite, tachycardia, twitching or convulsions. There is no specific antidote for overdose.
  • Use cautiously in liver disease and assess risk versus benefit in pregnancy. Age, cardiac disease, diet, illness and interacting medicines can alter exposure; individualise monitoring rather than assuming one capsule schedule fits every dog.
  • For bronchitis, confirm the cause and treat airway inflammation and other disease-specific factors; bronchodilator response is variable. This product is an adjunct, not proof that every chronic cough is bronchitis.
  • The SPC retains a congestive-heart-failure indication, but that legacy claim is not evidence to replace current diagnosis-specific cardiac treatment. Confirm the cardiac diagnosis and follow contemporary standard care.
Assessment sources
  1. VMD SPC 20252025
  2. VMD Corvental D current2026
  3. Corvental sustained-release PK1993
  4. MSD Vet Manual 20242024
  5. Canine sustained-release comparison1998
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Theophylline100 mg
Formulation Type
Modified release (retard / SR)
Administration route
By mouth
Manufacturer
-
Registration
Georgia No
Not registered in Georgia
Veterinary (National Food Agency)
Verified on: 15 Oct 2026
 EU No
Verified on: 15 Oct 2026
 UK Yes, veterinary
Verified on: 15 Oct 2026
 US No
Verified on: 15 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026

Corvental D 200 mg, Modified release (retard / SR)

sustained-release hard capsule, for dogs
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog
6.2/10
Situational / acceptable
vetman assessment

Corvental D

200 mg, sustained-release hard capsule, for dogs
Assessed clinical scopeDog · Labelled once-daily sustained-release theophylline as an adjunct for canine bronchitis; the legacy congestive-heart-failure label claim requires diagnosis-led reassessment against current cardiac standard care · By mouth
Care settingVeterinary-prescribed home treatment after respiratory and cardiac diagnosis, with exact weight-based capsule selection, interaction review and response and toxicity monitoring
vetman score 6.2/10 Situational / acceptable
Evidence confidence: Medium Georgia: No · Verified on 15 Oct 2026

A currently authorised, exact canine sustained-release product that may help selected bronchitis patients, but the undivided 200 mg step limits dose precision. Use only after diagnosis and interaction review, and do not treat the legacy heart-failure label claim as a replacement for current cardiac care.

Regulatory and scientific credibility8.0/10

The exact dog-only sustained-release presentations are currently authorised in Great Britain as prescription veterinary medicines, with a regulator-hosted 2025 SPC and product-specific pharmacokinetic evidence. They are not registered in Georgia, the pivotal study is small and more than three decades old, and no modern public benefit-risk reassessment of the full label scope was found.

Clinical efficacy5.5/10

A six-dog sustained-release study supports the labelled exposure and documented pharmacodynamic effects, and theophylline remains a recognised adjunct for canine bronchitis. However, no robust modern clinical outcome trial of Corvental D was found, response to bronchodilators is variable, anti-inflammatory treatment remains central, and the congestive-heart-failure claim is not evidence that theophylline substitutes for current diagnosis-specific cardiac therapy.

Safety and tolerability5.5/10

The exact SPC documents restlessness, gastrointestinal effects, polyuria and CNS excitation, contraindicates seizure history and beta-sympathomimetics, and identifies major metabolism and anaesthetic interactions. The therapeutic margin is narrow, convulsions may occur without preceding toxicity signs, and there is no specific antidote; liver disease, pregnancy and concurrent medicines require individual review.

Clinical practicality5.5/10

Once-daily home dosing is convenient, but the 200 mg modified-release capsule cannot be opened or divided and exactly supplies the label dose only in 10 kg increments. Accurate weighing and deliberate use of available strengths are essential because upward rounding can exceed 20 mg/kg.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Do not use in dogs with a history of epileptiform seizures. Convulsions have occurred without preceding toxicity signs and in apparently normal animals.
  • Concurrent beta-sympathomimetic use is contraindicated because additive or synergistic adverse effects may occur.
  • Macrolides and fluoroquinolones can increase theophylline exposure; phenobarbital and phenytoin can reduce it. Ketamine may further lower the seizure threshold and recent halothane exposure can increase arrhythmia risk. Review every medicine before treatment.
  • The modified-release capsule must be swallowed whole. Do not open, crush, chew or divide it; damaging the release system can create an unsafe peak and an unreliable dosing interval.
  • Weigh accurately and do not exceed 20 mg/kg once daily. Select whole capsules deliberately; never round upward merely to fit a strength. Consider plasma concentration monitoring when response, adherence, interactions or toxicity are uncertain.
  • Stop and reassess promptly for vomiting, diarrhoea, marked thirst or urination, restlessness, agitation, excitement, sedation, reduced appetite, tachycardia, twitching or convulsions. There is no specific antidote for overdose.
  • Use cautiously in liver disease and assess risk versus benefit in pregnancy. Age, cardiac disease, diet, illness and interacting medicines can alter exposure; individualise monitoring rather than assuming one capsule schedule fits every dog.
  • For bronchitis, confirm the cause and treat airway inflammation and other disease-specific factors; bronchodilator response is variable. This product is an adjunct, not proof that every chronic cough is bronchitis.
  • The SPC retains a congestive-heart-failure indication, but that legacy claim is not evidence to replace current diagnosis-specific cardiac treatment. Confirm the cardiac diagnosis and follow contemporary standard care.
Assessment sources
  1. VMD SPC 20252025
  2. VMD Corvental D current2026
  3. Corvental sustained-release PK1993
  4. MSD Vet Manual 20242024
  5. Canine sustained-release comparison1998
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Theophylline200 mg
Formulation Type
Modified release (retard / SR)
Administration route
By mouth
Manufacturer
-
Registration
Georgia No
Not registered in Georgia
Veterinary (National Food Agency)
Verified on: 15 Oct 2026
 EU No
Verified on: 15 Oct 2026
 UK Yes, veterinary
Verified on: 15 Oct 2026
 US No
Verified on: 15 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026

Corvental D 500 mg, Modified release (retard / SR)

sustained-release hard capsule, for dogs
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog
6.0/10
Situational / acceptable
vetman assessment

Corvental D

500 mg, sustained-release hard capsule, for dogs
Assessed clinical scopeDog · Labelled once-daily sustained-release theophylline as an adjunct for canine bronchitis; the legacy congestive-heart-failure label claim requires diagnosis-led reassessment against current cardiac standard care · By mouth
Care settingVeterinary-prescribed home treatment after respiratory and cardiac diagnosis, with exact weight-based capsule selection, interaction review and response and toxicity monitoring
vetman score 6.0/10 Situational / acceptable
Evidence confidence: Medium Georgia: No · Verified on 15 Oct 2026

A currently authorised, exact canine sustained-release product, but the undivided 500 mg capsule is practical only when it closely matches the calculated dose. Evidence is limited and old, the safety margin is narrow, and the legacy heart-failure label claim does not replace current cardiac standard care.

Regulatory and scientific credibility8.0/10

The exact dog-only sustained-release presentations are currently authorised in Great Britain as prescription veterinary medicines, with a regulator-hosted 2025 SPC and product-specific pharmacokinetic evidence. They are not registered in Georgia, the pivotal study is small and more than three decades old, and no modern public benefit-risk reassessment of the full label scope was found.

Clinical efficacy5.5/10

A six-dog sustained-release study supports the labelled exposure and documented pharmacodynamic effects, and theophylline remains a recognised adjunct for canine bronchitis. However, no robust modern clinical outcome trial of Corvental D was found, response to bronchodilators is variable, anti-inflammatory treatment remains central, and the congestive-heart-failure claim is not evidence that theophylline substitutes for current diagnosis-specific cardiac therapy.

Safety and tolerability5.5/10

The exact SPC documents restlessness, gastrointestinal effects, polyuria and CNS excitation, contraindicates seizure history and beta-sympathomimetics, and identifies major metabolism and anaesthetic interactions. The therapeutic margin is narrow, convulsions may occur without preceding toxicity signs, and there is no specific antidote; liver disease, pregnancy and concurrent medicines require individual review.

Clinical practicality4.5/10

Once-daily home dosing is convenient, but the 500 mg modified-release capsule cannot be opened or divided and represents the full daily label dose for a 25 kg dog. It is inflexible for many patients and must not be rounded upward or opened; use a smaller strength or another formulation when the whole-capsule dose does not fit.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Do not use in dogs with a history of epileptiform seizures. Convulsions have occurred without preceding toxicity signs and in apparently normal animals.
  • Concurrent beta-sympathomimetic use is contraindicated because additive or synergistic adverse effects may occur.
  • Macrolides and fluoroquinolones can increase theophylline exposure; phenobarbital and phenytoin can reduce it. Ketamine may further lower the seizure threshold and recent halothane exposure can increase arrhythmia risk. Review every medicine before treatment.
  • The modified-release capsule must be swallowed whole. Do not open, crush, chew or divide it; damaging the release system can create an unsafe peak and an unreliable dosing interval.
  • Weigh accurately and do not exceed 20 mg/kg once daily. Select whole capsules deliberately; never round upward merely to fit a strength. Consider plasma concentration monitoring when response, adherence, interactions or toxicity are uncertain.
  • Stop and reassess promptly for vomiting, diarrhoea, marked thirst or urination, restlessness, agitation, excitement, sedation, reduced appetite, tachycardia, twitching or convulsions. There is no specific antidote for overdose.
  • Use cautiously in liver disease and assess risk versus benefit in pregnancy. Age, cardiac disease, diet, illness and interacting medicines can alter exposure; individualise monitoring rather than assuming one capsule schedule fits every dog.
  • For bronchitis, confirm the cause and treat airway inflammation and other disease-specific factors; bronchodilator response is variable. This product is an adjunct, not proof that every chronic cough is bronchitis.
  • The SPC retains a congestive-heart-failure indication, but that legacy claim is not evidence to replace current diagnosis-specific cardiac treatment. Confirm the cardiac diagnosis and follow contemporary standard care.
Assessment sources
  1. VMD SPC 20252025
  2. VMD Corvental D current2026
  3. Corvental sustained-release PK1993
  4. MSD Vet Manual 20242024
  5. Canine sustained-release comparison1998
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Theophylline500 mg
Formulation Type
Modified release (retard / SR)
Administration route
By mouth
Manufacturer
-
Registration
Georgia No
Not registered in Georgia
Veterinary (National Food Agency)
Verified on: 15 Oct 2026
 EU No
Verified on: 15 Oct 2026
 UK Yes, veterinary
Verified on: 15 Oct 2026
 US No
Verified on: 15 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026

Professional reference for veterinary professionals. Not advertising and not a substitute for the product label/SPC.

For veterinary professionals only. It does not replace clinical judgement or the product label; check the dose in the official label (SPC). vetman is not liable for harm caused by using this information.

Trademarks belong to their owners; vetman is not affiliated with the manufacturers and receives no payment from them.

The database is protected under Chapter VII of the Law of Georgia on Copyright and Related Rights; automated or bulk copying is prohibited.

This reference is still growing. Missing a product? Let us know. · Report an error or request an addition · Updated: 16 Oct 2026

All of this shows in vetman as you prescribe

The dose for the patient's weight, registration in Georgia and controlled status, right on the prescription.

Register Demo ↗